Celanese

CENYSEUSD

THESIS ALERT

Email me when the CE thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$51.45
+$2.52 (+5.15%)Today 1M +8.69%
After hours$51.450.00%

Updated Nov 11, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$48.93
Prior regular-session close from the quote source.
$48.93–$51.48
Regular-session low and high so far today.
1.5M
Regular-session shares traded · Nov 11, 4:00 PM ET.
Feb 16 projected
Projected for 2027-02-16 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
$35.13–$70.70
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own CE if today’s earnings collapse is cyclical and its qualified materials franchise plus acetyl-chain scale can fund deleveraging before structurally weaker spreads impair the equity.

CE price history

Latest price$51.45Today+$2.52 (+5.15%)
CE +14.31%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Customer qualification and specification requirements in Celanese’s materials applications should keep the company relevant with OEM and industrial customers through the cycle, but this needs calibration because segment retention, volumes and pricing are not supplied.HoldingMateriality: High

    GAAP annual revenue remained large at $9.544 billion in FY2025, showing Celanese still has meaningful customer demand despite a weak period. If application stickiness holds, cyclical demand recovery can convert into revenue without Celanese having to buy volume through price; if it breaks, the company becomes a more commodity-like producer.

    Watch: Automotive, electronics or industrial OEMs redesign products around lower-cost substitute resins from competitors such as BASF, SABIC, Covestro or DuPont.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual revenue remained large at $9.544 billion in FY2025, showing Celanese still has meaningful customer demand despite a weak.

    Open source ↗
  • Celanese’s acetyl-chain scale and integration should provide spread resilience when industry utilization normalizes, but this claim is currently under pressure from lower gross profit and needs calibration without segment spread data.WeakeningMateriality: High

    GAAP annual gross profit was still positive at $1.952 billion in FY2025. If acetyl spreads recover, gross profit can rebound meaningfully; if overcapacity permanently resets spreads, Celanese’s earnings power is lower than historical results imply.

    Watch: New Chinese acetic acid, VAM or related acetyl capacity from producers such as Wanhua, Sinopec or other regional competitors keeps global utilization low even after demand normalizes.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual gross profit was still positive at $1.952 billion in FY2025.

    Open source ↗
  • Celanese’s portfolio should be able to generate operating cash even while GAAP earnings are depressed, giving management time to fix margins and reduce leverage.StrengtheningMateriality: Medium

    GAAP annual operating cash flow was positive at $1.146 billion in FY2025 despite a GAAP annual net loss. Positive cash flow gives equity holders a path through the downturn; if cash conversion fails, leverage and refinancing risk can dominate the investment case.

    Watch: A working-capital rebuild absorbs cash as inventories and receivables rise before margins recover.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating cash flow was positive at $1.146 billion in FY2025 despite a GAAP annual net loss.

    Open source ↗
  • Management must prioritize balance-sheet repair so cash generation accrues to equity value rather than being consumed by refinancing risk, dilution or distressed asset sales.HoldingMateriality: Medium

    Total liabilities declined from $20.167 billion at FY2022 year-end to $17.223 billion at FY2025 year-end. Deleveraging can transfer value back to shareholders; failure to reduce liabilities leaves the equity highly exposed to downturns and creditor claims.

    Watch: Credit-rating pressure or debt covenants force refinancing on unfavorable terms before earnings recover.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Total liabilities declined from $20.167 billion at FY2022 year-end to $17.223 billion at FY2025 year-end.

    Open source ↗
  • Celanese’s fixed-cost manufacturing network can recover earnings power only if volume, mix and pricing restore plant utilization without forcing price concessions.WeakeningMateriality: Medium

    GAAP annual operating income was positive at $1.378 billion in FY2022 and $1.665 billion in FY2023, demonstrating prior earnings capacity. Operating leverage is the difference between a cyclical rebound and a value trap: higher utilization could rapidly improve earnings, while weak utilization leaves gross profit unable to cover fixed costs.

    Watch: Automotive, construction, electronics or broad industrial demand remains weak even after normal inventory cycles should have ended.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating income was positive at $1.378 billion in FY2022 and $1.665 billion in FY2023, demonstrating prior earnings capacity.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Customer qualification and specification requirements in Celanese’s materials applications should keep the company relevant with OEM and industrial customers through the cycle, but this needs calibration because segment retention, volumes and pricing are not supplied. If application stickiness holds, cyclical demand recovery can convert into revenue without Celanese having to buy volume through price; if it breaks, the company becomes a more commodity-like producer.

Celanese’s acetyl-chain scale and integration should provide spread resilience when industry utilization normalizes, but this claim is currently under pressure from lower gross profit and needs calibration without segment spread data. If acetyl spreads recover, gross profit can rebound meaningfully; if overcapacity permanently resets spreads, Celanese’s earnings power is lower than historical results imply.

Celanese’s portfolio should be able to generate operating cash even while GAAP earnings are depressed, giving management time to fix margins and reduce leverage. Positive cash flow gives equity holders a path through the downturn; if cash conversion fails, leverage and refinancing risk can dominate the investment case.

Management must prioritize balance-sheet repair so cash generation accrues to equity value rather than being consumed by refinancing risk, dilution or distressed asset sales. Deleveraging can transfer value back to shareholders; failure to reduce liabilities leaves the equity highly exposed to downturns and creditor claims.

Celanese’s fixed-cost manufacturing network can recover earnings power only if volume, mix and pricing restore plant utilization without forcing price concessions. Operating leverage is the difference between a cyclical rebound and a value trap: higher utilization could rapidly improve earnings, while weak utilization leaves gross profit unable to cover fixed costs.

All standing thesis claims
Original report summary

today’s earnings collapse is cyclical and its qualified materials franchise plus acetyl-chain scale can fund deleveraging before structurally weaker spreads impair the equity.

Evidence assessed Oct 15, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Celanese

Where the evidence on Celanese disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 5 thesis points, 1 strengthening, 2 holding and 2 weakening.

Bull case: what the evidence supports

  • Customer qualification and specification requirements in Celanese’s materials applications should keep the company relevant with OEM and industrial customers through the cycle, but this needs calibration because segment retention, volumes and pricing are not supplied.

    sec.gov ↗

  • Celanese’s portfolio should be able to generate operating cash even while GAAP earnings are depressed, giving management time to fix margins and reduce leverage.

    sec.gov ↗

  • Management must prioritize balance-sheet repair so cash generation accrues to equity value rather than being consumed by refinancing risk, dilution or distressed asset sales.

    sec.gov ↗

Bear case: what the evidence questions

  • Celanese’s acetyl-chain scale and integration should provide spread resilience when industry utilization normalizes, but this claim is currently under pressure from lower gross profit and needs calibration without segment spread data.

    sec.gov ↗

  • Celanese’s fixed-cost manufacturing network can recover earnings power only if volume, mix and pricing restore plant utilization without forcing price concessions.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Celanese

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed Celanese’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Director or principal officer change.

    Celanese filed an SEC 8-K on 2026-09-16: Director or principal officer change. It is a dated development that tests the current thesis.

  2. Mixed
    Regulation FD disclosure.

    Celanese filed an SEC 8-K on 2026-08-04: Regulation FD disclosure. It is a dated development that tests the current thesis.

  3. Mixed
    Reported results of operations (earnings release).

    Celanese filed an SEC 8-K on 2026-08-04: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Automotive, electronics or industrial OEMs redesign products around lower-cost substitute resins from competitors such as BASF, SABIC, Covestro or DuPont.
  • New Chinese acetic acid, VAM or related acetyl capacity from producers such as Wanhua, Sinopec or other regional competitors keeps global utilization low even after demand normalizes.
  • A working-capital rebuild absorbs cash as inventories and receivables rise before margins recover.
  • Credit-rating pressure or debt covenants force refinancing on unfavorable terms before earnings recover.
  • Automotive, construction, electronics or broad industrial demand remains weak even after normal inventory cycles should have ended.

CE news

Loading headlines…

Financial statements

CE income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

CE: quick answers

When does Celanese (CE) report earnings next?
Celanese's next results are projected for February 16, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 2, 2026. Earnings calendar
What is CE's short interest?
As of October 30, 2026, 6.1M CE shares were sold short, 5.58% of its shares outstanding, up 5.9% from the count before. At the stock's average daily volume that is 4.6 days to cover. FINRA publishes the count twice a month. CE short interest history
Have members of Congress traded CE?
Reports made public in the last 90 days disclose 2 trades in CE by 1 filer: 0 purchases and 2 sales. They are filed under the STOCK Act by members of Congress, the President and senior officials. Every disclosed CE trade
Which well-known investors own CE?
1 of the 37 well-known funds tracked here reported CE shares in their latest 13F filing. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios

CE in well-known investors’ portfolios

1 of 37 funds reported CE shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.

FundOf its portfolioValueChangeQuarter
Ray DalioBridgewater Associates0.02%$5.4M+1.8%Q2 2026

Every fund’s portfolio

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.